Defense Worldยท2025-11-23 07:38Core Insights - Aurinia Pharmaceuticals is generally favored over PMV Pharmaceuticals based on a comparison of various financial and operational metrics, outperforming PMV in 10 out of 13 factors analyzed [10]. Analyst Ratings - Aurinia Pharmaceuticals has a consensus target price of $17.67, suggesting a potential upside of 12.67%, while PMV Pharmaceuticals has a target price of $5.00, indicating a potential upside of 278.79% [2]. Risk & Volatility - Aurinia Pharmaceuticals has a beta of 1.3, indicating its share price is 30% more volatile than the S&P 500, whereas PMV Pharmaceuticals has a beta of 1.54, meaning its share price is 54% more volatile than the S&P 500 [3][4]. Institutional and Insider Ownership - 36.8% of Aurinia Pharmaceuticals shares are held by institutional investors, compared to 90.2% for PMV Pharmaceuticals. Insider ownership stands at 12.2% for Aurinia and 7.6% for PMV [5]. Profitability - Aurinia Pharmaceuticals has a net margin of 23.31%, return on equity of 20.06%, and return on assets of 13.81%. PMV Pharmaceuticals does not have net margin data available, with a return on equity of -55.34% and return on assets of -51.01% [7]. Earnings and Valuation - Aurinia Pharmaceuticals reported gross revenue of $265.81 million, a net income of $5.75 million, and earnings per share of $0.56, with a price-to-earnings ratio of 28.00. PMV Pharmaceuticals has no revenue reported, a net loss of $58.71 million, earnings per share of -$1.60, and a price-to-earnings ratio of -0.83 [9].